

Targeting **HER2-Low** Expression in Breast Cancer

Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

CME-Certified Live Symposium

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Friday, 9 September 2022
10:15–11:45 CEST

7.3.H - Honfleur Auditorium, Hall 7, Level 7.3
Paris Expo Porte de Versailles, Paris, France



CHAIR & PRESENTER

Prof. Aleix Prat, MD, PhD


Hospital Clínic Barcelona
University of Barcelona
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Barcelona, Spain



PRESENTER

Shanu Modi, MD

Memorial Sloan Kettering Cancer Center
New York, New York



PRESENTER

Paolo Tarantino, MD

Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Agenda

- **10:15 CEST: Symposium**
 - Welcome and Introduction (*Prof. Aleix Prat, MD, PhD*)
 - Understanding the Foundational Concepts of HER2-Low Breast Cancer: Challenges and Opportunities of an Evolving Definition (*Paolo Tarantino, MD*)
 - Extending Anti-HER2 Therapy Benefits to a Larger Population of Patients: Emerging Evidence, Implementation in Clinical Practice, and Future Directions (*Shanu Modi, MD*)
 - Unveiling the Biology of HER2-Low Breast Cancer: Insights From Genomics, Transcriptomics, and Opportunities With Evolving Testing Approaches (*Prof. Aleix Prat, MD, PhD*)
 - Exploring the Nuances of HER2-Targeted Treatment Selection for Patients With HER2-Low Breast Cancer: Expert Insights Into Implications for Practice and Team-Based Approaches to Individualizing Patient Care (*All faculty panel discussion*)
 - Summary, Reflections, and Key Takeaways
- **11:45 CEST: Adjourn**

Key Reasons to Attend:

- Better understand the biologic concept and evolving definition of HER2-low breast cancer
- Learn how to implement new HER2 testing methods, principles, and best practices to identify patients with HER2-low breast cancer
- Get expert guidance on navigating the impressive, rapidly accumulating evidence supporting the use of novel HER2-targeted therapies in HER2-low breast cancer and integrating these agents into treatment plans for appropriate patients